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Abstract
Background: At many outpatient departments for psychiatry worldwide, standardized monitoring of the safety of
prescribed psychotropic drugs is not routinely performed in daily clinical practice. Therefore it is unclear to which
extent the drugs used by psychiatric outpatients are prescribed effectively and safely. These issues warrant structured
monitoring of medication use, (pre-existing) co-morbidities, effectiveness and side effects during psychiatric outpatient
treatment. Improvement of monitoring practices provides an opportunity to ensure that somatic complications and
adverse drug effects are detected and dealt with in a timely manner. Structural support for data collection and follow-
up tests seems essential for improvement of monitoring practices in psychiatric outpatients. The implementation of a
structured somatic monitoring program as part of routine clinical practice, as we describe in this study protocol, may
be a solution.
Methods: In order to address these issues, we developed the innovative program ‘Monitoring Outcomes of Psychiatric
Pharmacotherapy (MOPHAR)’. MOPHAR is an infrastructure for implementation of standardized routine outcome
monitoring (ROM; including standardized monitoring of treatment effect), monitoring of adverse psychotropic
medication effects in psychiatric outpatients, encompassing both somatic adverse effects (e.g. metabolic
disturbances) and subjective adverse effects (e.g. sedation or sexual side effects) and medication reconciliation.
Discussion: In the MOPHAR monitoring program, a nurse performs general and psychotropic drug-specific
somatic screenings and provides the treating mental health care providers with more and better information on
somatic monitoring for treatment decisions. Given our experience regarding implementation of the MOPHAR
program, we expect that the MOPHAR program is feasible and beneficial for patients in any MHS organisation.
This paper describes the objectives, target population, setting and the composition and roles of the treatment
team. It also indicates what measurements are performed at which time points during outpatient treatment in
the MOPHAR monitoring program, as well as the research aspects of this project.
Trial registration: MOPHAR research has been prospectively registered with the Netherlands Trial Register on
19th of November 2014. (NL4779).
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Background
Severe mental illness patients are expected to live a 13–30
year shorter life compared to the general population [1, 2].
Somatic co-morbidities such as cardiovascular disease, nu-
tritional and metabolic diseases and pain may account for
approximately two-thirds of this excess mortality [1, 3, 4].
This increased somatic morbidity and mortality may be
contributed to by various factors, including an unhealthy
lifestyle (directly or indirectly associated with psychopath-
ology of the patient) and disparities in health care provision
and access, associated with the psychiatric disease [1, 5].
Also, psychotropic drugs may cause and/or increase the
vulnerability of patients with mental illness to somatic ad-
verse drug effects [1, 6]. Metabolic syndrome and other
somatic complications do not only occur in schizophrenia
patients or patients using antipsychotics. Mood disorders
are also known to negatively influence lifestyle [7, 8]. More-
over, these disorders are commonly treated with combina-
tions of lithium, mood stabilizers, antipsychotics and
antidepressants. These patients are therefore at risk for de-
veloping somatic complications too [9, 10]. In addition, psy-
chiatric patients are generally less inclined to use health
care services and have a decreased perception of illness
compared to the general population [11].
Worldwide, at many specialized outpatient clinics for
psychiatric disorders, systematic monitoring of the safety
of prescribed drugs is not routinely performed in daily
clinical practice. Previous research from our group has
indicated that medication reconciliation and monitoring
of somatic parameters are not routine clinical practice at
outpatient departments for mood and anxiety disorders
in the north of The Netherlands [12, 13]. Likewise, in a
large benchmarking audit in lithium-treated patients
from The United Kingdom, weight, body mass index
(BMI) and waist circumference had not been recorded
in 72% of 2976 patients, (follow-up) tests on kidney and
thyroid function had not been performed in 19 and 18%
of patients respectively, and lithium serum concentration
had not been taken in 9% [14]. A meta-analysis of 39
studies (n = 218,940) investigating metabolic syndrome
in patients with mostly schizophrenia or related disor-
ders and that were using antipsychotics, showed that
baseline metabolic screening before commencement of
pharmacotherapy was suboptimal and in more than 50%
of patients only blood pressure and triglycerides blood
concentrations were checked [15]. Research in somatic
departments shows that between 90 and 100% of HIV
patients are regularly screened on hypertension, diabetes
and dyslipidaemia, which is considerably higher than
40–70% in psychiatric outpatients taking antipsychotics.
This suggests particularly poor monitoring in patients
with psychiatric problems [16]. Furthermore, there may
be considerable medication discrepancies between the
medication overview at the psychiatric outpatient clinic
and the actual medication use by the patient [12]. In
conclusion, monitoring of side effects (associated with
prescribing psychotropic medication) and medication
use has generally not been systematically implemented
in daily psychiatric practice. Therefore it is unclear to
which extent the drugs used by psychiatric outpatients
are prescribed safely. These issues warrant systematic
somatic monitoring of (pre-existing) co-morbidities, side
effects and medication use, during psychiatric outpatient
treatment.
Improving monitoring practices may ensure that som-
atic co-morbidities and adverse drug reactions are de-
tected and treated in a timely manner. Unfortunately,
the introduction of new guidelines, education materials,
(national) quality improvement programs or consensus
statements alone have shown only minimal improve-
ment in monitoring practices [15, 17–20]. There are sev-
eral potential reasons for this lack of effectiveness of
these strategies. For example, the documents or mate-
rials may not reach all relevant health care professionals
in the expected time frame, awareness of the need for
improvement of monitoring practices may be lacking or
resources for local implementation of the recommenda-
tions may be unavailable.
Taken together, structural support of mental health care
professionals for data collection and follow-up testing at a
local or regional level seems essential for improvement of
monitoring practices in psychiatric outpatients. Imple-
menting a structured somatic monitoring program that is
incorporated in routine clinical practice may be a solution
[21]. In order to address these issues, we developed the in-
novative monitoring program ‘Monitoring Outcomes of
Psychiatric Pharmacotherapy (MOPHAR)’. MOPHAR is
an infrastructure for implementation of standardised rou-
tine outcome monitoring (ROM; including standardised
monitoring of treatment effect), monitoring of objective
somatic adverse effects including metabolic disturbances
as well as subjective symptoms such as sedation or sexual
side effects of psychiatric pharmacotherapy and medica-
tion reconciliation in outpatients. This monitoring pro-
gram added to standard psychiatric treatments, also
provides the opportunity to build a patient registry for the
conduct of research on topics such as physical complica-
tions, side effects of medication and monitoring care in
psychiatric outpatients.
Although it seems logical to monitor and treat known
complications of psychiatric disease and psychotropic
medication, the evidence for benefits of monitoring spe-
cific (sets of) parameters (and subsequent treatment if in-
dicated) in terms of for example less somatic
complications, better quality of life or shorter treatment
duration is lacking. The (cost)effectiveness of monitoring
of specific (sets of) parameters needs to be established to
provide an evidence base for investing in implementation
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of systematic monitoring programs and reimbursement by
health care insurance companies. This paper describes the
research aspects of the MOPHAR study as well as the
process and measurements of the MOPHAR monitoring
program.
Methods/design
MOPHAR research
Apart from a somatic monitoring care path for routine
clinical practice, the MOPHAR monitoring program also
provides the opportunity for long-term (longitudinal)
prospective and retrospective observational cohort stud-
ies. The large amount of information collected in the pa-
tient registry of MOPHAR can be used for research:
many questions may be answered in retrospective stud-
ies, including association studies and prediction models
on the effect and side effects of psychotropic drugs.
Because apart from all current patients, also all new pa-
tients are asked for informed consent to be included in
MOPHAR, the sample size will increase in time. The
sample sizes for analyses will be pre-specified per indi-
vidual research question.
Next to retrospective studies, MOPHAR also gives the
perspective for future prospective studies. After imple-
mentation of MOPHAR there is a structured program in
place with uniform moments for evaluation by a
MOPHAR nurse. These moments can be used for future
prospective interventions as well. Furthermore, patient
and treatment characteristics are gathered systematically
thereby allowing selection of patients suited for specific
prospective studies.
The general research objectives are:
1. To investigate the association between patient
characteristics and outcomes (e.g. (cost)effectiveness,
adverse effects) of psychiatric pharmacotherapy.
Amongst others the association between
pharmacogenetic determinants/biomarkers and the
prevalence of adverse effects of antidepressants will
be investigated.
2. To investigate the association between the use of
specific psychotropic drugs and adverse effects like
metabolic abnormalities in selected samples and the
unselected population (population-based research).
In addition we will be able to set up intervention
studies targeting such adverse effects.
Our research objectives reflect both the aim to investi-
gate how we can most efficiently detect the relevant sig-
nals for somatic complications and the aim to
investigate how we can predict which patients will prob-
ably benefit from specific psychotropic drugs and/or are
vulnerable for specific side effects. Results of these stud-
ies can be used to prevent, monitor and treat adverse
effects in the near future. More specific research ques-
tions will be formulated per individual study within
MOPHAR, along with theoretical frameworks and spe-
cific definitions, if applicable. In addition, the statistical
analyses plans will be described per individual research
question. We expect to use for example regression ana-
lysis techniques and longitudinal data analysis tech-
niques (for clustered data), including mixed effects
models.
Informed consent
MOPHAR research has been registered with the
Netherlands Trial Register (NL4779; https://www.trialre-
gister.nl/trial/4779). The research aspects of MOPHAR
were approved by the independent medical ethics com-
mittee (RTPO 928, rTPO Leeuwarden, The
Netherlands), and all participants provide written in-
formed consent. We ask general informed consent to
conduct research on the data collected in the MOPHAR
monitoring program including the linkage of the clinical
data with an extra blood sample obtained for MOPHAR
research (see below under ‘extra blood sample’). Subjects
can withdraw from further participation in the
MOPHAR research cohort at any time for any reason
without any consequences regarding their treatment and
MOPHAR monitoring care.
Study population
For every research question addressed in MOPHAR, the
appropriate study population will be determined within
the MOPHAR cohort from the patient registry. In general,
eligible patients meet the following inclusion criteria:
older than 18 years of age and visiting an outpatient de-
partment of MHS Drenthe (first time or follow-up visit,
i.e. newly referred and current patients) are eligible for
inclusion in MOPHAR).There are no general exclusion
criteria for inclusion in the MOPHAR patient registry.
Extra blood sample
For research purposes, an extra blood sample (20 ml)
will be taken from each subject. This blood sample will
be taken at the same time as one of the blood sample
withdrawals for routine clinical practice. Therefore, no
additional venepuncture is necessary and no additional
risks are associated with this single study procedure.
This blood sample can be used for future research (for
example, pharmacogenetics and biomarker research) to
investigate associations between drug or patient charac-
teristics and treatment success and/or the prevalence of
somatic side effects concerning scientific questions re-
lated to psychiatric health issues for which the patient
visited the outpatient department.
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Objectives of the MOPHAR monitoring program
The primary objective of the MOPHAR monitoring pro-
gram is to systematically provide mental health care pro-
viders with more and better information for treatment
decisions and to facilitate monitoring of the treatment
effect and adverse effects of psychiatric pharmacotherapy
in psychiatric outpatients.
Secondary objective is to enable routine collection of
longitudinal monitoring data of daily psychiatric practice
for research purposes. The general research objectives
have been discussed above.
Target population and setting
The MOPHAR monitoring program targets adult pa-
tients (≥ 18 years) referred to mental health care out-
patient clinics for any psychiatric diagnosis. Patients can
be referred by their general practitioner or by a mental
health care treatment officer from another department
or institution. Any information on the psychiatric symp-
toms, co-morbidities and medication use that has been
noted in the referral letter is incorporated in the avail-
able information for the initial visit for MOPHAR. After
referral and initial visit at the outpatient clinic, regular
mental health care at the general practitioner’s practice
stops. MOPHAR accommodates patients either at initial
visit or already in treatment at the outpatient clinic at
the time of implementation.
The MOPHAR monitoring program is currently im-
plemented at a large secondary community mental
health care outpatient department. However, in its
current form, it can be implemented at any mental
health care outpatient clinic serving a broad population
of persons with a (severe) mental illness. While a core
set of elements and monitoring measurements is pro-
vided in MOPHAR, the current program as described in
this paper does not preclude access to other somatic
services or program amendments fitted to specific popu-
lations (e.g. disease-specific measurements or question-
naires or paper-based instead of online questionnaires
for elderly patients).
The MOPHAR treatment team
The MOPHAR treatment team is multidisciplinary. The
MOPHAR team comprises the regular treatment team
with at least one psychiatrist, at least one psychiatric
nurse trained in the somatic screening of MOPHAR and
a secretary. However, usually more than one person per
discipline is involved, as well as a psychologist and a
nursing specialist. There is a flexibility in the size and
composition of the team.
The roles of the different team members can be de-
scribed as follows. The secretary plans the appointments
and invites the patient, which marks the start of the
MOPHAR monitoring program for individual patients.
The psychiatric nurse performs the MOPHAR screen-
ings. To this end, in a one-day session the psychiatric
nurses are trained by the MOPHAR pharmacist in the
logistics of the MOPHAR monitoring program and how
to perform medication reconciliation, how to enter the
medication use in the electronic prescribing system and
how to register the MOPHAR screening results. The
medication prescriber (i.e. psychiatrist or nursing spe-
cialist) is responsible for decisions on and execution of
interventions and follow-up based on the results of the
MOPHAR screenings along with the psychiatric treat-
ment. The team must identify a clear workflow regard-
ing the communication of results with other relevant
health care professionals (e.g. general practitioner). At
MHS Drenthe, the primary treatment officer sends a
summary of the findings from the MOPHAR screenings
to the general practitioner. The prescriptions are sent to
the community pharmacy.
Members of the MOPHAR treatment team may have
collateral responsibilities to MOPHAR patients or other
non-MOPHAR (inpatient) teams. In addition, the nurses
can be scheduled interchangeably for different outpatient
teams to perform MOPHAR screenings if necessary.
This flexibility may be a major appeal of the MOPHAR
model of somatic monitoring for mental health care in-
stitutions. Since somatic monitoring is in part recom-
mended in Dutch guidelines, MOPHAR is meant to be
fitted into the usual workflow of the team. However,
extra resources are needed for training, supervision, im-
plementation and support. Implementation and project
support are provided by a project manager and a
pharmacist to ensure project progress and resolve prac-
tical issues. The pharmacist is responsible for training
the MOPHAR nurses (e.g. medication reconciliation)
and the quality assurance of the established (psycho-
tropic drug-specific) monitoring protocols. In addition,
the pharmacist can be consulted by the treatment team
with medication-related questions.
The MOPHAR monitoring process and protocols
Figure 1 shows the general process of the MOPHAR
monitoring program. MOPHAR is an addition to the
established routine clinical practice at the outpatient
clinics. Because outpatients are simultaneously treated
for their psychiatric disorder by different mental health
care providers (e.g. a psychiatrist, psychologist, nursing
specialist (nurse with a Master of Advanced Nursing
Practice, allowed to treat patients independently or in
some specialized settings under supervision of the
psychiatrist) and/or psychiatric nurse), the appointments
for a MOPHAR screening and the invitations to fill in
online questionnaires are planned together as much as
possible, shortly before the appointments with the men-
tal health care provider(s). Frequency of attendance
Simoons et al. BMC Health Services Research          (2019) 19:125 Page 4 of 10
ranges between once in 3 months and twice weekly, de-
pending on factors such as stage and acuteness of illness,
illness severity and intensity of treatment; for MOPHAR
they visit the clinic at least at initial visit and yearly, with
additional (combined) visits if they (start to) use psycho-
tropic medication.
Somatic screening at first appointment
A general somatic screening is performed at the first ap-
pointment, irrespective of (differential) diagnosis or medi-
cation use. This general somatic screening (±45min)
serves to screen for existing somatic co-morbidities, side
effects of drugs already in use (e.g. metabolic distur-
bances), and potential (additional) causes of the mental ill-
ness (e.g. thyroid dysfunction for depression). In addition,
it may serve as a baseline screening before start of psycho-
tropic drug treatment if applicable.
Online patient-filled questionnaires
In the invitation letter for the first appointment, patients
are asked to fill in questionnaires about their demo-
graphics, family history of psychiatric disease, smoking,
Fig. 1 Schematic presentation of health care and study procedures in MOPHAR. All procedures shown are performed as a part of routine daily
clinical practice. Routine Outcome Monitoring (ROM; online patient-filled questionnaires) has to be completed at certain time points, but not with
all MOPHAR appointments
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alcohol and illicit substance use and previous psychiatric
(pharmacotherapeutic) treatments. These questionnaires
have been developed by the department of Psychiatry of
the University Medical Centre Groningen, The
Netherlands (HGR) [22]. In addition, the World Health
Organisation Disability Assessment Schedule (WHO--
DAS) 2.0 [23] and the Diagnostic and Statistical Manual
of Mental Disorders (DSM)-5-level 1-questionnaire [24]
on general psychiatric symptoms are filled in. The
WHO-DAS 2.0 is a generic assessment of a patient’s
health and disability, and with the results of the
DSM-5-level 1-questionnaire the psychiatrist can assess
in which mental health domains a patients experiences
symptoms that need further examination because they
may have a significant influence on the treatment and
prognosis. The Outcome Questionnaire (OQ)-45 is
added for non-elderly adult patients, to monitor treat-
ment outcomes and general functioning [25]. Further-
more, an 18-item questionnaire is filled in about the
presence of subjective symptoms and potential drug side
effects. This questionnaire, called the Somatic Mini
Screen (SMS), is developed by MHS Central, The
Netherlands, and is in the process of validation (internal
validity has been confirmed, inter- and intra-rater reli-
ability is currently investigated). Lastly, at least one
disorder-specific questionnaire is added to the set, de-
pending on the patient population (e.g. the
patient-completed self-report of the Inventory of De-
pressive Symptomatology (IDS-SR) in mood disorder pa-
tients). All questionnaires can be filled in by the patient
through an online secured patient portal, that is inte-
grated with the electronic medical records. This takes
patients on average 60–90min in total. We currently use
RoQua, which is a patient portal that is accessible via
the electronic medical records and is used by several as-
sociated mental health care institutions [26]. In case a
patient does not have access to or skills in using a com-
puter and/or internet or the electronic medical records
are unavailable, a paper based version of the question-
naires can be completed. Eventually, the whole
MOPHAR program can be implemented
non-electronically. Furthermore, and alternatively, extra
computers are available at the outpatient services that
patients can use to fill in the questionnaires, sometimes
with the aid of the nurse. The nurse checks whether all
requested questionnaires have been filled in completely
before the screening, so any missing information can be
added during the appointment.
Screening appointment with MOPHAR nurse
During the MOPHAR screening visit, roughly four types
of monitoring information are collected by the trained
nurse (Fig. 1). First, a basic physical examination, includ-
ing measurements of body mass index (BMI), waist
circumference, blood pressure and heart rate. An elec-
trocardiogram (ECG) can be added on indication.
Second, laboratory measurements. A nursing specialist
or doctor orders the laboratory tests on a paper-based
laboratory order form. The laboratory associated with
MOPHAR has developed a dedicated laboratory order
form for MOPHAR, on which the applicant can order
all test from one measurement moment with one check.
The nurse can perform the venepuncture, but patients
from most teams are asked in the invitation for the
appointment to go to the laboratory for blood with-
drawal in the week before the screening with the labora-
tory order form sent along with the invitation. The total
set of physical and laboratory measurements collected is
shown in Supplemental Table 1 [see Additional file 1].
This protocol has been written in 2014 by a Dutch
multidisciplinary working group, consisting of psychia-
trists (including BD and HGR), (hospital) pharmacists
(HM, MS) and a clinical chemist. The monitoring rec-
ommendations were based on the available national and
international relevant monitoring guidelines to start with
[27–31], but since there was a paucity thereof, the proto-
col was mostly based on clinical experience and expert
opinion of the members of the working group. In 2015,
the new guideline ‘Somatic screening of patients with a
severe mental illness’ was published in The Netherlands,
in which similar recommendations were described to
those in the MOPHAR protocols [32].
Third, two structured interviews: one regarding som-
atic disease history of the patient and first-degree family
members and the other regarding the patient’s lifestyle,
including physical exercise and diet. The nurse com-
pletes these with the patient through the online portal in
the electronic medical records.
Last, medication reconciliation. This is performed by
the nurse through a combination of the pharmacy re-
cords and patient counselling. In preparation of the
screening appointment, the nurse requests a medication
overview (including medication and allergies or intoler-
ances) from the community pharmacy of the patient by
fax. At the screening appointment, the nurse reconciles
this overview with the actual medication use by inter-
viewing the patient. Medication reconciliation provides
an up-to-date and complete medication overview includ-
ing all drugs currently in use and all medication allergies
or intolerances that the nurse enters in the electronic
prescribing system. In case of relevant medication dis-
crepancies (compared to the pharmacy records), the
MOPHAR nurse will notify the psychiatrist/nursing
specialist.
Availability of the screening results
The information collected via questionnaires beforehand
and during the MOPHAR screening is immediately
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available to the mental health care provider via the
patient portal and serves as a starting point for the
anamnesis, psychiatric examination and a (semi-)-
structured interview for diagnostic purposes. The pa-
tient portal generates a summary of all information
collected at the MOPHAR appointment. This sum-
mary selects a set of pre-specified most relevant
parameters for a quick assessment of the clinical sta-
tus of the patient, together with the information on
medication use and laboratory tests.
Yearly somatic screenings
The general somatic screening at the first appointment
is repeated yearly in all patients (±30 min), irrespective
of psychiatric diagnosis or medication use. However,
with respect to the patient-filled online questionnaires,
only the smoking/alcohol/illicit substance use question-
naire, the WHO-DAS 2.0, the DSM-5 screener, and the
SMS are repeated at the yearly screening as well as the
disorder-specific questionnaire and OQ45 (if applicable).
Psychotropic drug-specific monitoring
In addition to the general somatic screenings at the first
appointment and yearly thereafter, the MOPHAR nurse
conducts additional screenings according to
drug-specific monitoring protocols if a patient starts
with or already uses one or more psychotropic drugs
(±30 min per appointment). To this end, the abovemen-
tioned multidisciplinary working group has additionally
written MOPHAR monitoring protocols per psycho-
tropic drug (class). The monitoring protocols are shown
in Additional files 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12 [27,
29, 30, 33–38]. The time points for the follow-up mea-
surements differ per drug because of the different time-
line of occurrence of side effects, but have been
clustered as much as possible within each drug and be-
tween drugs to reduce the number of appointments and
venepunctures. This makes the protocols uniform and
enables clustering of follow-up measurements in patients
using multiple psychotropic drugs.
In order to monitor subjective side effects, the SMS
questionnaire is repeated three monthly when psycho-
tropic medication is used. The physical exercise and life-
style questionnaire (filled in by the nurse during a
MOPHAR appointment) may also be repeated in the
course of monitoring of psychotropic medication use.
Medication reconciliation is performed by the nurse at
MOPHAR appointments or by the medication prescriber
(i.e. psychiatrist or nursing specialist) if medication is
prescribed, stopped or changed.
Interpretation and follow-up of MOPHAR results
The summary generated from the patient portal, the
medication overview from the electronic prescribing
system and the laboratory test results together provide a
full picture of the patient for the weekly to monthly
multidisciplinary meeting where interventions and
follow-up are planned [39]. A recent study by Bruins et
al. (2016) showed that despite prevalences of the meta-
bolic syndrome in > 50% at three yearly assessments in
the PHAMOUS monitoring program for schizophrenia
patients, half of the patients were not treated for their
metabolic risk factors [39]. We will propose standardized
interventions to facilitate the treatment of and follow-up
on deviating test results by the responsible health care
provider.
Protocol evaluation
Apart from the abovementioned adjustments to fit spe-
cific populations, the core set of monitoring program el-
ements will be adjusted over time. There is on ongoing
debate regarding the necessity and appropriate fre-
quency of monitoring of parameters such as the ECG
[40, 41], liver function [42] and blood counts [43]. Also,
monitoring items might be added to the program. For
example, pharmacogenetics testing is not part of the
protocol but the multidisciplinary group might decide to
add pharmacogenetics testing to the program in the
future [44]. The protocol therefore needs a yearly evalu-
ation in a plan-do-check-act cycle to keep it up-to-date
and adjusted to best clinical practices and new
guidelines.
Discussion
MOPHAR current status and future perspectives
The MOPHAR monitoring program is currently incor-
porated in routine psychiatric care at the outpatient de-
partments of MHS Drenthe after the assignment and
approval for the implementation from the general board
of MHS Drenthe. Eventually, all approximately 5700
adult patients with a (differential) diagnosis of a psychi-
atric disorder who are annually referred to a psychiatrist
or psychologist at the MHS Drenthe outpatient depart-
ments will be asked to participate in MOPHAR. After
that, we aim to implement MOPHAR at other mental
health care institutions and also include patients from
these other centres in MOPHAR research.
To the best of our knowledge, we are the first to de-
scribe a comprehensive monitoring program that ac-
tively supports mental health care professionals to
implement guideline-concordant general somatic and
psychotropic-specific monitoring of psychiatric patients
in daily clinical practice, that is flexible to accommodate
patients with any psychiatric diagnosis. Two monitoring
programs have been described in the literature which, al-
though with a similar level of active support, focused on
psychotic patients only and/or on metabolic syndrome
screening and monitoring [45, 46].
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Implementation of MOPHAR started at the outpatient
department for bipolar disorders. First appointment
somatic screenings took place from January 2016 on-
ward and yearly somatic screenings from November
2016 to synchronize MOPHAR with the individual
yearly treatment evaluation schemes for patients that
were already in treatment. Results of the first appoint-
ment somatic screenings for the outpatient department
for bipolar disorders have been reported separately [47].
At this moment a general practitioner is not part of
the treatment team. In the near future we would like to
add this professional in order to ensure patient-centred
care, including the treatment of detected somatic com-
plications and adverse drug effects. Other potential fu-
ture innovations of the program are a digital assurance
system to ascertain protocol adherence and standardized
interventions on aberrant test results where possible. In
addition, the monitoring program may be adjusted for
implementation in first-line health care-organizations,
thereby serving the target population throughout the
continuum of relevant (mental) health care providers for
psychiatric outpatients.
Conclusion
Psychiatric patients are vulnerable for somatic
co-morbidities and side effects of psychotropic medication.
However, current monitoring frequencies of somatic health
of these patients may be low. There is a need for structural
support for improvement of somatic monitoring practices
in psychiatric outpatients in line with available monitoring
guidelines. The active implementation of a structured mon-
itoring program in which somatic monitoring is ensured as
part of routine clinical will provide be a possible solution.
In addition, it provides the opportunity to establish a
patient registry for research purposes. In the MOPHAR
monitoring program, a nurse performs general and psy-
chotropic drug-specific somatic screenings and provides
the treating mental health care providers with more and
better information on somatic monitoring for treatment
decisions. Given our experience regarding implementation
of the MOPHAR program, we expect that the MOPHAR
program including the research aspects is feasible and
beneficial for patients in any MHS organisation.
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